Ikena to discontinue development of IK-930
IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date
Ended first quarter with $157.3 million; Exploring strategic options to maximize shareholder value
https://www.globenewswire.com/news-release/2024/05/28/2889468/0/en/UPDATE-Ikena-Oncology-Announces-Strategic-Update.html
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.